3 unknown, 1 terminated. 4 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Unknown 3, Terminated 1 |
| Phase 2 | 2 | Unknown 2 |
Follow nafamostat: new trials by email Literature Review of nafamostat trials Research Report on nafamostat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of Nafamostat in Covid-19 Patients (RACONA Study) Nafamostat Mesilate, Placebo - COVID19 | Phase 2 / Phase 3 | Unknown | University Hospital Padova | 256 | 2021-06-04 | 2023-11-01 |
| Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal Nafamostat Mesilate - COVID-19 | Phase 3 | Terminated | Institut Pasteur de Dakar | 59 | 2020-08-13 | 2024-06-21 |
| Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial (Arm Closed) Nafamostat Mesilate, (Arm Closed) Enoxaparin, (Arm Closed) Dalteparin - SARS-CoV-2 Infection (COVID-19) | Phase 3 | Unknown | University of Melbourne | 2200 | 2020-07-28 | 2024-05-16 |
| Clinical Efficacy of Nafamostat Mesylate for COVID-19 Pneumonia Nafamostat Mesylate - Corona Virus Infection, COVID-19 | Phase 2 / Phase 3 | Unknown | Gyeongsang National University Hospital | 84 | 2020-06-10 | 2020-06-09 |
COVID-19 (4) · Coronavirus Infections (2) · Pneumonia (1)
Gyeongsang National University Hospital (1) · Institut Pasteur de Dakar (1) · University Hospital Padova (1) · University of Melbourne (1)
Australia (1) · Italy (1) · Senegal (1)
Amadou A. Sall, PhD (1) · Fabien Taieb, MD, PhD (1) · Gian Paolo Rossi, Prof. (1) · Moussa Seydi, MD (1) · Steven Tong, Prof (1)
PMID 32142651, PMID 11594901, PMID 25822153, PMID 27550352, PMID 30536180, PMID 32171076, PMID 32187464, PMID 32312781, PMID 33502773, PMID 34814935, PMID 34953516, PMID 35244208, PMID 36514143, PMID 38320033, PMID 38320527